Free Trial
NASDAQ:ELOX

Eloxx Pharmaceuticals (ELOX) Stock Price, News & Analysis

Eloxx Pharmaceuticals logo

About Eloxx Pharmaceuticals Stock (NASDAQ:ELOX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.00
$0.75
52-Week Range
N/A
Volume
37 shs
Average Volume
1,745 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

Receive ELOX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eloxx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ELOX Stock News Headlines

‘Wheels Are Falling Off’ the U.S. Stock Market
The last time the U.S. economy looked like this, stocks didn't move for 16 years... And many investors lost 80% of their wealth in real terms. But before you touch any of your holdings – or buy anything – please review my latest warning about the U.S. stock market. It's free to watch.
Eloxx Pharmaceuticals Inc (ELOX)
See More Headlines

ELOX Stock Analysis - Frequently Asked Questions

Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) posted its earnings results on Monday, April, 3rd. The company reported ($2.92) EPS for the quarter, topping analysts' consensus estimates of ($2.97) by $0.05.

Shares of ELOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eloxx Pharmaceuticals investors own include Tesla (TSLA), ADMA Biologics (ADMA), Adverum Biotechnologies (ADVM), Assertio (ASRT), Fulcrum Therapeutics (FULC), Acasti Pharma (ACST) and Akebia Therapeutics (AKBA).

Company Calendar

Last Earnings
4/03/2023
Today
4/18/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ELOX
Employees
30
Year Founded
2013

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
2,508,000
Optionable
Not Optionable
Beta
-1,519.43
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:ELOX) was last updated on 4/18/2025 by MarketBeat.com Staff
From Our Partners